In this phase3 trial, researchers explored whether a chemotherapy-free strategy was superior to a tyrosine kinase inhibitor plus chemotherapy in Ph-positive ALL.

In this study, researchers calculated a national estimate of lung cancer screening-eligible individuals, including estimates based on demographic variables and geographic regions.

New ACOG guidance says benefits outweigh risks for most women, with nonhormonal options for those who can’t take hormones ...

The application for the next-generation mitomycin formulation is supported by 3-month complete response data from the phase 3 UTOPIA trial.

In this analysis, researchers examined the association of quality of life and functional outcomes with organ preservation following total neoadjuvant treatment among patients with rectal cancer.

In the LIGHT trial, researchers compared carbon dioxide laser therapy and sham laser therapy for breast cancer survivors receiving AIs who presented with GSM and dyspareunia.

Inverse correlation reported for pathogenic variant prevalence with age at diagnosis, but prevalence was 12.3 percent in late-onset tumors ...

Dr Don Dizon discusses how social media can break down barriers between clinicians and patients and why oncologists should ...

Hematologist and oncologist, Dr Amit Garg, MD, discusses using social media platforms to combat hematology and oncology ...

In this study, researchers aimed to analyze the effect of communicating uncertainties about the benefits and risks of new cancer drugs on patients’ decision to take the drug.

Women who had genetic testing for inherited cancer risk years ago may want to ask about testing again, experts say. A person’s genes don’t change. But testing has come a long way, and many early tests ...

The expansion marks the first therapy approved for patients with BCG-unresponsive non-muscle-invasive bladder cancer presenting with papillary-only disease.